Press release

BioInvent Interim Report 1 January - 30 September 2011

  · Recruitment of patients for BioInvent's phase II studies is progressing according to plan and we expect to report topline results for BI-204 (coronary artery disease) in the second quarter of next year and for TB-402 (thrombosis) in the second half of next year.

  · In order to speed up patient recruitment to our expanded phase I study with BI-505 (multiple myeloma) we will include new clinical centres. We expect patient recruitment to continue into the first quarter of next year.

  · In May Roche initiated a phase Ib/II study with drug candidate TB-403 in patients with glioblastoma multiforme. In March Roche initiated a phase Ib study in patients with primary liver cancer.

  · A private placement of SEK 136 million before transaction costs was completed in June at a share price of SEK 22.30. About twenty investors participated, mainly institutions, and the majority of the new shares were subscribed for by international investors.

  · Net revenues for January - September 2011: SEK 123 million (76). Loss for January - September 2011 amounted to SEK -7.9 million (-86) and the loss per share amounted to SEK -0.12 (-1.42).

  · Current investments together with cash and bank as of 30 September 2011: SEK 217 million (144). Cash flow from current operations and investment activities for January - September 2011: SEK -18 million (-85).

BioInvent is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects mainly within the areas of thrombosis, cancer, acute coronary syndrome and inflammation.

Comments by the CEO
BioInvent's clinical development program progresses on all fronts towards next year's important study read-outs. The outcome of these studies will be of fundamental importance to the future of the Company.

I expect the last patient in the BI-204 study to start the three-month treatment period around year-end, which should allow us to report topline results by Q2 next year. In the TB-402 study more than half of the centres participating are now treating patients, which is in line with the expected ramp-up.

The study with our candidate antibody drug BI-505 in patients with advanced multiple myeloma is well into its second year. In order to accelerate recruitment of patients we have decided to include additional centres to the three existing ones. By including additional centres we also hope to be able to make use of the option in the study protocol to expand the number of patients treated at the highest dosing levels. Patient recruitment will then continue into next year's first quarter.

Svein Mathisen

Contact
Any questions regarding this report will be answered by:

BioInvent International AB (publ.)
Svein Mathisen, President & CEO, tel.+46 (0)46 286 85 67, mobile +46 (0)708 97 82 13
Sten Westerberg, Vice President, Investor Relations, tel. +46 (0)46 286 85 52, mobile +46 (0)768 68 50 09.

College Hill
Melanie Toyne Sewell, Anastasios Koutsos, tel. +44 (0)20 7866 7856, [email protected] ([email protected])
Rebecca Skye Dietrich, tel: +1 857 241-0795.

The report is also available at www.bioinvent.com (http://www.bioinvent.com/)

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET, on 13 October, 2011.